Diabetes In Control. A free weekly diabetes newsletter for Medical Professionals. News and information for Medical Professionals.
Semaglutide trumps Trulicity in most recent trial.
Read More »Semaglutide Beats Dulaglutide in Head-to-Head Trial
GLP-1 Agonist Has CV Benefits
New study shows lower risk for poor cardiovascular outcomes for T2 patients on glucagonlike peptide-1 receptor agonists.
Read More »Using a GLP-1 Agonist to Prevent Type 2
Results determined for 3-year study of liraglutide versus placebo diabetes risk reduction and weight management in individuals with prediabetes.
Read More »GLP-1 Receptor Agonist for Type 1’s
Besides lowering A1c, study finds success with using less insulin and weight reduction.
Read More »Liraglutide Reduces Liver Fat Content in Patients With Poorly Controlled Type 2 Diabetes
A proposed benefit of GLP-1 agonists confirmed in a human study.
Read More »AACE: Complete Reversal of Type 2 Diabetes With GLP-1 Agonist
Retrospective analysis presentation shows liraglutide (LIRA) improved glycemic parameters, reduced body weight, BMI, and waist circumference in new T2 patients.
Read More »Importance of GI Events for GLP-1 Receptor Agonists
Study finds fewer T2 patients on exenatide once-weekly reported gastrointestinal adverse events, compared with those on exenatide twice-daily or liraglutide once-daily.
Read More »Use of Liraglutide in Obese Patients May Reduce Risk for Type 2 Diabetes
A new finding from the SCALE trial.
Read More »Effectiveness of A GLP-1 Receptor Agonist Plus A TZD for Type 2 Diabetes
Therapy said superior to a basal/bolus insulin regimen at lowering HbA1c with less hypoglycemia and weight gain.
Read More »FDA Approves 2 New Diabetes Combos
IDegLira, LixiLan go head-to-head; FDA approves Novo Nordisk’s Xultophy and Sanofi’s Soliqua on the same day.
Read More »